



The potential for immunoglobulins and host defense peptides (HDPs) to reduce the use of antibiotics in animal production

van Dijk, Albert; Hedegaard, Chris Juul; Haagsman, Henk P.; Heegaard, Peter Mikael Helweg

Published in:
Veterinary Research

Link to article, DOI:
[10.1186/s13567-018-0558-2](https://doi.org/10.1186/s13567-018-0558-2)

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
van Dijk, A., Hedegaard, C. J., Haagsman, H. P., & Heegaard, P. M. H. (2018). The potential for immunoglobulins and host defense peptides (HDPs) to reduce the use of antibiotics in animal production. *Veterinary Research*, 49, [68]. <https://doi.org/10.1186/s13567-018-0558-2>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

REVIEW

Open Access



The potential for immunoglobulins and host defense peptides (HDPs) to reduce the use of antibiotics in animal production

Albert van Dijk^{1†}, Chris J. Hedegaard^{2†}, Henk P. Haagsman^{1*‡}  and Peter M. H. Heegaard^{2‡}

Abstract

Innate defense mechanisms are aimed at quickly containing and removing infectious microorganisms and involve local stromal and immune cell activation, neutrophil recruitment and activation and the induction of host defense peptides (defensins and cathelicidins), acute phase proteins and complement activation. As an alternative to antibiotics, innate immune mechanisms are highly relevant as they offer rapid general ways to, at least partially, protect against infections and enable the build-up of a sufficient adaptive immune response. This review describes two classes of promising alternatives to antibiotics based on components of the innate host defense. First we describe immunoglobulins applied to mimic the way in which they work in the newborn as locally acting broadly active defense molecules enforcing innate immunity barriers. Secondly, the potential of host defense peptides with different modes of action, used directly, induced in situ or used as vaccine adjuvants is described.

Table of Contents

- 1 Introduction
- 2 Innate host defense mechanisms
- 3 Immunoglobulins
 - 3.1 Immunoglobulins as innate host defense molecules
 - 3.2 Immunoglobulin strategies for control of infectious disease in production animals
- 4 Host defense peptides
 - 4.1 Regulation of endogenous HDP production
 - 4.1.1 Transcriptional control
 - 4.1.2 Post-translational and secretion control
 - 4.1.3 Developmental control
 - 4.2 Antimicrobial strategies involving HDPs
 - 4.2.1 Induction of endogenous HDP production
 - 4.2.2 HDP-derived antimicrobials

- 4.2.3 HDP-derived immunomodulators
- 4.2.4 HDPs as adjuvants for vaccines
- 4.2.5 HDPs as adjuncts in antibiotic therapy

5 Conclusions

References

1 Introduction

Resistance of microbes to antimicrobial agents is a global threat. An increasing number of pathogenic bacteria has been shown to readily develop resistance against antibiotics (antimicrobial resistance, AMR) of different structural classes. The continuous selective pressure of antibiotic residues in the environment has led to the generation of multi-resistant superbugs, some of which are resistant against every antibiotic known to mankind. In addition, vast amounts of antibiotics related to those used in human medicine are still used in animal husbandry to prevent disease outbreaks, while elsewhere in the world antibiotics are used as growth promoters. For example, in Denmark two-thirds of the total prescribed antibiotics are used in animal production [1]. Similar figures apply throughout the EU [2, 3]. The practice of factory farming in which production animals are kept in high densities and numbers facilitates the generation of

*Correspondence: H.P.Haagsman@uu.nl

[†]Albert van Dijk and Chris J. Hedegaard contributed equally to this work

[‡]Henk P. Haagsman and Peter M. H. Heegaard are senior authors

¹ Division Molecular Host Defence, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

Full list of author information is available at the end of the article




AMR reservoirs. Currently, it is not possible to determine the contribution that the use of antibiotics in agriculture is making to the emerging nosocomial AMR. However, there is consensus that minimizing the use of antimicrobials in agriculture is essential to safeguard antimicrobials for human medicine and that alternative strategies are needed to reduce the use of antibiotics in animal husbandry. In particular infectious diseases with a mucosal infection component dominate the veterinary antibiotics demand and alternative strategies to handle such diseases can thus be expected to have a major impact on the total antibiotics usage in animal production and will be instrumental in achieving a significant decrease in the total usage (i.e. animal and human combined) of antibiotics in regions with large intensive animal production sectors.

As illustrated schematically in Figure 1, bacterial infections will all be treatable with antibiotics. In the animal production sector some will also be treatable or preventable by alternative antibacterial methods such as management measures (e.g. regarding hygiene, animal density, controlling environment and feed etc.) and vaccination [4]. However, a certain proportion will not be treatable by these alternative methods and for those, innate immunology based methods described in this review may be used as alternatives to antibiotics. An important group of such “difficult” infections are infections at mucosal surfaces to which efficient memory immune response are notoriously difficult to raise by vaccination. Importantly, as indicated in Figure 1, a need for antibiotics will remain; however, the implementation of alternative methods will drastically reduce the consumption and frequency of use of antibiotics in animal production, reducing a potential major driver of general AMR development. It should be borne in mind however that, unless specific legislation is imposed, the implementation of any alternative method in the animal production sector depends heavily upon efficiency, ease of use and low cost.

2 Innate host defense mechanisms

The generalized host reactions towards infection, aimed at quickly containing and removing the infectious micro-organism are collectively known as the innate host defense. The innate immune system is an evolutionary ancient part of host defense. It is present in all organisms; it has a limited repertoire of defense molecules, and a broad specificity. This defense is accomplished by a highly coordinated sequence of events profoundly changing the population of cellular and soluble factors in the affected tissue leading to restored tissue homeostasis, terminating the acute phase of the response and activating adaptive immune responses. Innate defense mechanisms include activation of local stromal and immune cells, the induction of cytokine and chemokine messengers and



the resulting attraction and activation of neutrophils/heterophils, macrophages and natural killer (NK) cells, the induction of effector molecules such as enzymes, collectins, acute phase proteins and host defense peptides, and, finally, the activation of the complement system. In addition, we define in this review maternal immunoglobulins acquired by offspring (passive immunity) as temporary innate host defense factors.


With recent discoveries of adaptive and memory properties of the innate immune system—so-called “trained innate immunity” [5]—the distinction between the innate and adaptive immune systems has become less well-defined. This presents new opportunities for shaping innate immunity and expands the potential of innate immunity based strategies. Trained immunity effects are established quickly (within days) and last for extended periods (months) and manifest themselves as a reprogramming of innate immune responses [6]. Examples include monocytes and macrophages treated with β -glucan or BCG (*Bacillus Calmette–Guérin*) vaccines becoming hyper-responsive with an increased reactivity

towards various, unrelated immune triggers [7]. On the other hand, exposure of monocytes to vitamin A renders them less responsive to microbial ligand stimulation [8]. Dendritic cells, neutrophils, NK cells and other classical innate immune cell types can be affected in similar ways by other types of pathogen associated molecular patterns (PAMPs) of bacteria and other microorganisms [5]. These effects can be observed after resolution of an infection as an altered reaction to a subsequent, unrelated infection [5] and they presumably also are the reason for the “off-target”—effects observed as a side effect of a number of vaccines [6]. Some of these effects are epigenetically based [9] working by modifying histone accessibility and typically affect signal transduction pathways and/or transcription factors, adaptors etc. [10]. Such mechanisms represent unexplored opportunities to “strengthen” immunity which is a desired goal of immune-based intervention with potential to decrease the need for antibiotics; however, before large scale applications in animal farming can be envisaged more needs to be known about basic mechanisms and especially on how specific, desired training effects can be achieved without leading to unwanted effects on innate immune reactivity in general (Figure 2).

Well described soluble components with important functions in the innate immune system include cytokines and chemokines as well as the host defense peptides that are described in detail below and which are remarkable in having both direct antibacterial effects as well as immunomodulatory effects on the host immune system. Cytokines and chemokines can be considered immune system “hormones” with very powerful effects both in the vicinity of the producer cell (auto- and paracrine action) and systemically (endocrine action) [11]. Some of them

have highly specific effects such as the chemokines which act as chemo-attractants for neutrophil granulocytes while others have a surprisingly wide range of effects depending on the type of cell binding the cytokine (pleiotropic cytokines) [11]. This latter characteristic together with their endocrine actions (systemic effects) makes the use of certain cytokines as drugs challenging [12]. Even so, some cytokines show early promise (such as IL-22 [13, 14]) and some have been tested successfully for controlling infection in production animals [15]. Thus, bovine G-CSF (granulocyte colony stimulating factor) was reported to have a significantly reducing effect on the number of cattle with clinical mastitis as well as on the absolute neutrophil counts in a herd investigation involving 211 periparturient Holstein cows and heifers given two doses of PEGylated (polyethylene glycol-attached) bovine G-CSF subcutaneously at day-7 and 1 after parturition [16]. One additional major factor preventing the further development and use of cytokines for control of infections in animal production is that it will be hard to manufacture these compounds at an efficiency/price ratio comparable to antibiotics at the doses needed and furthermore that injection-based drugs will generally be less acceptable to the farmers.

This review describes the anti-bacterial mechanisms and possibilities of use as alternatives to antibiotics of two types of molecules representing extremes of the innate immune system and two very different strategies. These alternatives comprise natural immunoglobulin pools obtainable in large amounts from inexpensive sources and intended to be used for oral administration (feed supplement) and host defense peptides, either induced *in situ* or administered. For a review on immunomodulatory phytochemicals the reader is referred to the article of Lillehoj et al. in this issue.



3 Immunoglobulins

3.1 Immunoglobulins as innate host defense molecules


Conceptually, pre-existing immunoglobulins (antibodies), which are the effector molecules of humoral immunity, can be conceived as part of the innate immune defense as they reinforce the barriers against infection put up for immediate and general protection by the innate immune system *per se*. In the neonate, the innate selection of antibodies acquired during gestation through the placental blood supply or post-delivery by ingestion of colostrum and milk is also a part of the innate defense system at the mucosal surfaces of the digestive tract as well as in the circulation. The total pool of immunoglobulins, present or readily produced by primed plasma cells at mucosal surfaces and in the circulation, shares the property of broad reactivity, across a wide variety of microbial pathogens with other innate host

defense molecules and systems. In the adult animal, the total immunoglobulin pool is shaped by the cumulative pathogen exposure experienced by the host during its lifetime. In the newborn, immunoglobulins are supplied directly by the mother. This happens in the fetal stage by transplacental transfer supplemented by oral intake of colostrum and milk after birth in animal species having a hemochorial placenta, including primates (Figure 3). In animal species with an epitheliochorial placenta (such as pigs and ruminants) transplacental transfer does not take place and the newborn animal is therefore born without circulating immunoglobulins which must be supplied by the colostrum and milk by lactation (lactogenic immunity) [17]. This principle is used throughout the animal kingdom including birds and fish in which passive transfer of immunity takes place in ovo, dating back at least 450 million years in the evolution [18]. In all cases the newborn is provided with the polyclonal and polyspecific maternal immunoglobulin pool, representing the maternal antibody repertoire induced against the whole spectrum of pathogens experienced by the maternal host throughout her life. For transplacentally supplied immunoglobulins this pool is simply an aliquot of the circulating pool of immunoglobulins in the maternal blood, while in mammals depending on colostrum and milk immunoglobulins the origin depends on the immunoglobulin type. Thus, secretory IgA (sIgA) which is the dominating milk immunoglobulin in primates is mainly produced by local plasma cells in the lymphoid mucosal

tissue of the mammary gland. These sIgA producing plasma cells are part of the so-called gut-associated lymphoid tissue (GALT) that also extends to the gut and therefore reflects the antigenic specificities of antibodies induced in the gut. In animal species in which the dominating milk immunoglobulin is IgG (e.g. pigs and cattle), milk immunoglobulins are derived from circulating plasma cells that feed IgG into the mammary gland via an active Fc-receptor mediated transcytosis process that favors specific immunoglobulin classes and subclasses over others, such as IgG1 in bovine [17].

An adequate level of circulatory immunoglobulins has been shown to be of the utmost importance for the disease-free survival of the newborn [19, 20].

In man, the main immunoglobulin type in colostrum and milk is sIgA which is specialized to function at mucosal surfaces such as in the intestinal tract and is not absorbed by the gut. Conversely, in animals born without circulating immunoglobulins IgG is the predominating immunoglobulin type in colostrum and mother's milk and it is transferred by Fc-receptor mediated active transport from the gut to the circulation in the newborn only within the first 24 h after birth, where after the gut does not allow anymore immunoglobulin absorption. This ensures a very rapid (perinatal) establishment of adequate circulatory levels of immunoglobulins in the newborn providing innate protection against a broad spectrum of infections. Thus maternally derived immunoglobulins protect the offspring until the immune system of



the newborn has matured to a state where it can itself respond with adequate adaptive immune responses and build up an immunological memory of its own. In mammals, maternal antibodies have been shown to persist for 2–5 weeks in the offspring (with some variation between species (see Table 1 in [18]).

Immunoglobulins counteract infectious disease by a range of mechanisms including preventing the adhesion and/or entry into host cells of bacteria and viruses, binding to and neutralizing extracellular toxins, enchain-ing growth of bacteria, accelerating their clearance as shown for IgA [21], opsonizing bacteria i.e. tagging them for destruction by the complement system, and promoting of antibody-dependent, cell-mediated, cytotoxicity against bacteria and viruses [22, 23]. Immunoglobulins are remarkably stable proteins, being digested slowly in the intestinal tract compared to other proteins, IgA being even more stable than IgG [17] and retaining its antigen-binding activity even when partly degraded. Remarkably, bovine IgG₁ has been found to be just as proteolytically stable as bovine IgA [24].

3.2 Immunoglobulin strategies for control of infectious disease in production animals

The use of immunoglobulins for passive immunization has a long history in both human subjects and animals [25, 26]. The method is currently most often used to treat and/or prevent the effect of bacterial toxins, rabies virus post-exposure and bites and stings of toxic reptiles and scorpions [18]; however, the method is efficient against a broad range of both bacterial and viral infections [27]. A recent illustrative example is the treatment of Ebola virus infection using recombinant monoclonal antibodies (i.e. ZMapp [28]) and convalescent donor plasma having the ability to protect against disease development in human individuals post virus exposure [29, 30]. Immunoglobulins for human use can be administered either as antiserum, i.e. unpurified, as antibodies purified from human serum pools or as purified protein from cell culture (monoclonal antibody based drugs, a rapidly increasing area of drug development), typically using intravenous or intramuscular routes of administration.

A big number of methods exists for producing synthetic immunoglobulins and immunoglobulin derived molecules, for example by plant based expression, by viral expression, allowing administration in feed and upon infection with the virus, respectively. In this review we will purposefully focus on natural immunoglobulins, i.e. immunoglobulin obtained from biological fluids, notably blood and milk, in order to highlight the importance of these often overlooked sources of broad-spectrum antibodies.

Maternal vaccination has been used to protect piglets, lambs and calves against a variety of infectious diseases. Targeted pathogens include a wide variety of bacteria and also a number of viruses demonstrating the broad applicability of the passive immunization principle in immunologically immature stages such as the suckling stage (see [18]).

Also, as mentioned above, a number of licensed, immunoglobulin based products for passive immunization of animals exists (see Table 1, reproduced with permission [18]). A majority of these products is directed against bacterial toxins or bacteria as such; however, an equine IgG product for protecting horses against West Nile virus and a plasma product for restoring defective immunoglobulin plasma levels in horses are also included. Interestingly, many of these products are produced in another species than the target species, the majority is used parenterally and both purified and unpurified immunoglobulins products are available.

Not included in this table is spray-dried plasma (SDP) which is widely used in some animal production sectors for its growth promoting effects and its ability to alleviate widespread production diseases such as post weaning disease (PWD) in weaner piglets [31, 32]. The working mechanism of SDP is not fully known; however to a large extent it can be presumed to depend on its content of active immunoglobulins (approximately 20% of SDP dry weight is immunoglobulin) inhibiting the binding of pathogens to the intestinal mucosa and epithelium, as directly demonstrated [31]. This was further corroborated by the study by Pierce et al. [33] who demonstrated the growth promoting effect of SDP on early weaned pigs to reside in the IgG fraction, confirming that at least a part of the beneficial effect of SDP is due to its content of IgG and its action against intestinal pathogens.

Around 30% of the antibiotics used in the Danish pig production (which demands 75% of the veterinary use of antibiotics) is used to treat PWD [1]. Other big contributors to the veterinary consumption of antibiotics in Denmark and other regions include other intestinal diseases such as diarrhea in newborn and young calves.

In a series of experiments at National Veterinary Institute at the Technical University of Denmark the idea of targeting enteric infectious diseases such as PWD in pigs by oral immunoglobulin administration as a feed supplement was investigated prioritizing low production costs, ease of use and safety, all of which are crucial for an alternative to antibiotics to become widely accepted and used by farmers. While immunoglobulin can be produced using recombinant expression in seeds which can be used as a feed supplement [34] this does not readily allow to obtain the broad range of specificities needed to protect against a wide range of pathogens at the same time, and

Table 1 Licensed products for passive immunization of ruminants, horses and pigs.

Product type	Animal	Disease prevention/ targeted pathogens	Immunoglobulin type/origin	Administration (oral/parenteral)
<i>E. coli</i> specific antibodies	Calves	Scour	Bovine colostrum IgG/IgY	Oral
Antibacterial bovine serum antibodies	Cattle	<i>Arcanobacterium pyogenes</i>	Bovine serum	Parenteral
	Calves	<i>E. coli</i>		
	Sheep	<i>Mannheimia haemolytica</i>		
		<i>Pasteurella multocida</i>		
Clostridial antitoxins		<i>Salmonella typhimurium</i>	Equine Ig	Parenteral (sc and iv)
	Cattle	<i>Clostridium perfringens</i>		
	Calves	C&D		
	Goats	<i>Clostridium botulinum</i>		
	Sheep	C&B		
	Swine			
Tetanus antitoxin	Horses	Tetanus	Equine serum	Parenteral
	Cattle			
	Sheep			
	Swine			
	Goats			
Anti-West Nile virus antibodies	Horses	West Nile virus	Equine Ig	Parenteral
Anti-endotoxin antibodies	Horses	Septicaemia	Equine plasma from hyper-immune horses	Parenteral
Antibacterial plasma antibodies	Horses	<i>Rhodococcus equi</i> <i>E. coli</i> J-5	Equine plasma from hyper-immune horses	Parenteral
Equine plasma	Horses	Failure of passive transfer	Equine plasma	

Reproduced with permission from Hedegaard et al. [18]

the following studies therefore focused on immunoglobulin retrieved from natural sources.

First, to keep production costs low the purification of immunoglobulins from natural, inexpensive, easily accessible and processable sources was investigated; for pigs and cattle slaughterhouse blood is a relevant immunoglobulin source being inexpensive and renewable and, importantly having a high concentration (typically > 10 g/L) of immunoglobulins that must be assumed to have relevant specificities as long as the blood is sourced from the same species as intended for treatment and from the same epidemiological area as the target population. Upon slaughter one pig produces 2–3 L of blood which can be immediately collected and stabilized by addition of citrate to yield pig blood plasma. This is a streamlined, hygienic process put in place in most modern abattoirs and often used for producing the raw material for spray-dried plasma (see above) [35]. For poultry and fish a systematic and hygienic collection of abattoir blood is generally not in place; however, blood is evidently also in these cases a major side stream offering a source of highly concentrated immunoglobulin (IgY for poultry, tetrameric IgM for fish). Another inexpensive, renewable source of immunoglobulins is whey, especially of bovine origin. Whey contains roughly 0.7 g/L

immunoglobulin, which can be purified quickly by highly efficient methods that are also applicable to blood plasma (see below). In these investigations, for reasons of cost, it was specifically chosen not to prepare hyperimmune serum or whey by active immunization of donor animals; however, a hyperimmunization approach is also feasible if the preferred antigenic specificity is known and if the cost can be kept sufficiently low. Notably, with this approach avian eggs present themselves as containers of conveniently packaged highly concentrated IgY [36]. On average an egg yolk contains 100–150 mg of IgY amounting to at least 20 g of IgY per year per egg-laying hen [37].

Second, highly efficient methods are needed for purifying optimally active immunoglobulin at relatively low costs from large volumes of highly complex starting materials such as blood plasma and whey. This calls for affinity-based methods in the form of industrial scale formats, such as expanded bed adsorption chromatography as well as combined precipitation technologies such as affinity flocculation using polymeric ligands. Both types of processes employ mixed mode affinity ligands with proven group specific binding of immunoglobulins from a range of animal species [38]. These methods can be used to purify immunoglobulins from cattle, pigs, poultry and fish reaching purities in the 80% range in one

step (see e.g. [39]) with the added benefit of significantly reducing the concentration of any extraneous agents that might be present, including viruses (Hedegaard et al. unpublished results).

Third, purified immunoglobulin products need to be formulated for controllable and easy oral dosage and for compatibility with automatic feeding and/or drinking systems. In addition, formulation should ensure optimal shelf life at ambient temperature and optimal resistance against the protein denaturing and fragmenting environment of the gut. Last but not least, immunoglobulin products need to be certifiable concerning absence of adventitious agents, including viruses with relevance for pig production such as porcine circovirus type 2 (PCV2), porcine respiratory and reproductive syndrome virus (PRRSV) and porcine endemic diarrhea virus (PED).

Encouragingly, results indicated that purified porcine IgG (ppIgG) obtained from pooled slaughterhouse plasma and purified by expanded bed adsorption chromatography contained antibody reactivity against relevant porcine bacteria (*E. coli* O138, *E. coli* F4 and *E. coli* F18, as well as *Salmonella enterica* Diarizonae) but not against an irrelevant fish bacterium (*Yersinia ruckeri*) [39]. Additionally, it was observed in an *E. coli* O149 F4 challenge model in weaner piglets that piglets given ppIgG orally (4 g/day for 14 days) cleared the challenge strain faster and also had a lower proportion of enterobacteriaceae in their ileal microbiota upon slaughter at the end of the experiment than the control group that did not receive ppIgG [39]. No disease data are available from this experiment as no disease was seen after challenge and therefore a follow-up study was done in which disease was obtained upon challenge with the same *E. coli* type. In this experiment disease was counteracted by ppIgG (oral with feed, 3.8 g/day for 7 days) resulting in less clinical signs of diarrhea and clearance of the challenge strain just as fast as in piglets with access to feed supplemented with dietary zinc oxide for 10 days after weaning (2500 ppm) [40]. Interestingly, pre-feeding ppIgG for 5 days before challenge and continuing treatment for a total of 15 days did not improve protection compared to treatment for 7 days only, starting 1 day before challenge (at the day of weaning). Also of interest was that, while numbers of fecal hemolytic bacteria were reduced by both zinc and ppIgG treatment compared to the untreated group, non-hemolytic levels remained unchanged [40] suggesting a minimal effect of the IgG treatment on the normal microbiota. This would suggest that natural immunoglobulin pools do not contain appreciable activity directed against normal, homeostatic microbiota components, however this will need further investigations to be fully elucidated.

Preliminary work has shown some promising results using immunoglobulin from different sources and applied to other species. In a pilot experiment in which newborn calves were given IgG purified from bovine whey instead of colostrum for the first 24 h after birth the same titer of anti-rotavirus antibodies in the circulation was attained as in the control group having full access to colostrum. In another experiment, bovine immunoglobulin from whey was used as a supplement to colostrum and thereafter as a daily feed supplement for 28 days, leading to total IgG serum concentrations that were higher for the treated group at the end of the experiment (Larsen, Knudsen and Heegaard, unpublished). This shows that purified bovine IgG is readily taken up by the newborn calf. Also, results from this experiment suggested that at least some protection against disease was achieved by the intestinal presence of ingested IgG during the first month of the calf's life. Other preliminary results showed an effect on campylobacter colonization in chickens in a *Campylobacter jejuni* challenge model, using oral challenge and orally administered purified avian immunoglobulin (IgY) purified from blood (Barnhoff, Hoorfar and Heegaard unpublished). This indicates a possible use of the passive immunization principle to reduce the load of zoonotic bacteria in slaughtered animals (with the potential to improve product safety) for example by feeding immunoglobulin during a relatively short period prior to slaughter. These results support the concept that immunoglobulins with relevant activities can indeed be obtained from either slaughterhouse blood or milk/whey of non-immunized animal populations. The principle should be tested as a treatment or prevention option for other hard-to-treat enteric diseases of unknown or multifactorial infectious origin such as porcine epidemic diarrhea (PED), new neonatal porcine diarrhea (NNPD), and mink diarrhea, each of which have a major negative impact on production economy, and animal welfare and which are currently demanding the use of large amounts of antibiotics and/or spray dried plasma.

4 Host defense peptides

Host defense peptides (HDPs) have an essential role in protecting against microbial challenges due to their presence at host–environment interfaces and broad-spectrum antimicrobial and immunomodulatory activities. Host defense peptides (HDPs) are small peptides that are usually less than 100 amino acid residues long, mostly cationic (+2 to +9 for most peptides) and amphipathic and possess antimicrobial as well as immunomodulatory properties [41]. There are two HDP superfamilies, namely defensins that are β -sheet peptides stabilized by 3 disulfide bridges and can be subdivided into α -, β - and θ -defensins based on the spacing between these cysteine

residues, and cathelicidins that are produced as precursor proteins consisting of a signal peptide, cathelin-like domain and a mature bioactive peptide that is proteolytically cleaved off by serine proteases [42]. Cathelicidins can be classified based on the structures they can adopt when interacting with biological membranes, i.e. α -helical peptides (e.g. LL-37), hairpin peptides (e.g. bac-tenecin), extended peptides enriched in specific amino acids (e.g. indolicidin) [41] (Figure 4).

Although HDPs have been shown to exhibit broad-range antimicrobial activities against Gram-negative, Gram-positive bacteria, fungi, parasites and viruses, including multidrug-resistant strains [41], their capacity to modulate immune cells is increasingly gaining interest. HDPs such as the human cathelicidin LL-37 and human β -defensin-3 (hBD3) have shown to activate monocytes and other immune cells to produce chemokines and cytokines [43–45] and so indirectly stimulate recruitment of immune cells to the sites of infection. Due to their resemblance to chemokines HDPs may also directly attract neutrophils, monocytes, dendritic cells and T cells via C–C chemokine receptor type 2 or 6 (CCR2, CCR6) or *N*-formyl peptide receptor 2 (FPR2) receptors [46–48]. Several HDPs, including LL-37 and chicken

cathelicidin-2 (CATH-2), have shown to be anti-inflammatory, capable of neutralizing lipopolysaccharide- and lipoteichoic acid-induced pro-inflammatory cytokine and nitric oxide production [49–52]. Cathelicidins [51, 53] and defensins [54] were also found to enhance DNA-induced activation of macrophages due to enhanced endocytosis of DNA-peptide complexes.

4.1 Regulation of endogenous HDP production

A rich repertoire of HDPs is produced by epithelial cells at mucosal surfaces, skin and immune cells. HDPs are produced by different cells, but the HDP repertoire, cell and tissue distribution is species-specific. For instance, humans produce a single cathelicidin, LL-37, that is ubiquitously expressed and found in epithelial cells, neutrophils, macrophages, dendritic cells, B cells, NK cells and mast cells [55], whereas chicken cathelicidin-2 seems to be exclusively produced by heterophils [42], the avian counterpart of the mammalian neutrophil. Neutrophils and Paneth cells are primary producers of α -defensins, and α -defensins are expressed to a lesser extent by monocytes, lymphocytes and epithelium [55]. β -Defensins are expressed by epithelial cells, monocytes, macrophages, dendritic cells, but have also been found in heterophils




Figure 4 Three-dimensional representations of structures of chicken cathelicidin-2 (CATH-2), human cathelicidin LL-37, human defensin HBD-2, xenopus magainin-2 and the immunoglobulin IgG2a. Peptide chains are colored using a color gradient ranging from blue (N-terminus) to red (C-terminus). CATH-2 consists of a double helix separated by a hinge region, LL-37 and magainin-2 adopt a continuous helical structure and HBD-2 consists of an anti-parallel β -sheet structure. The IgG2a structure consists of an Fc fragment (blue/green), two ligand-binding Fab fragments (orange/yellow/green and red/green) and bound polysaccharide ligands NAG-FUC-NAG-BMA-MAN-NAG-GAL-MAN-NAG (blue) and NAG-FUL-NAG-BMA-MAN-NAG-GAL-MAN-NAG (green).

and enteroendocrine cells [55–57]. The expression, secretion and activity of HDPs are regulated in various ways, i.e. on the level of developmental transcription, post-translational processing and secretion.

4.1.1 Transcriptional control

Some HDPs are constitutively expressed, independent of microbial exposure, such as most gut α -defensins that are transcriptionally regulated via the Wnt pathway, an important signaling pathway [58, 59] and certain β -defensins [60]. Other peptides, including hBD2 (human β -defensin-2), require microbial ligands for full expression [60]. Transcriptional control of cathelicidins is cell-type specific, e.g. microbial induced upregulation in monocytes/macrophages and epithelial cells, while transcription in neutrophils predominantly occurs at the promyelocyte stage [42, 61].

4.1.2 Post-translational and secretion control

In humans and rodents, α -defensins are produced as inactive precursor proteins and stored inside granules in neutrophils and specialized enterocytes, so-called Paneth cells that are located in the intestinal crypts [59]. Upon recognition of microbial ligands by pattern recognition receptors at the cell surface granules are released in the crypt lumen. Similarly, cathelicidins and defensins are stored as inactive precursors in a subset of granules in mammalian neutrophils and avian heterophils [42, 62–64]. When recruited to a site of infection, contact with microbial ligands will trigger HDP release and their subsequent activation by serine proteases in the case of cathelicidins [42] and defensins depending on species and tissue amongst others by trypsin, kallikreins or matrix metalloproteinase-7 (MMP-7) [65]. Mammalian enteric β -defensins hBD1 (human β -defensin-1), mBD1 (mouse β -defensin-1) and mBD3 (mouse β -defensin-3) are constitutively produced [60] and released into the gut lumen where they contribute to the chemical barrier formed by the intestinal mucus layer. Other members of the α - and β -defensin families are regulated by microbial ligands [59, 66]. For example, Paneth cell α -defensins are released into the lumen through activation of intracellular nucleotide-binding oligomerization domain-like (NOD) receptors by bacterial muramyl dipeptide (MDP) [65] and neutrophil release of HDPs can be triggered by lipopolysaccharides (LPS) [42], whereas flagellin upregulates hBD2 in skin keratinocytes [67].

4.1.3 Developmental control

Abundant cathelicidin expression is present in the skin of human and murine neonates and is downregulated ten- to 100-fold in adults [68]. In chickens, the expression of the cathelicidin, CATH-2, peaks around hatch

[57]. The sterile surfaces of skin and mucosae are colonized after birth, and alter during weaning which evokes a shift in the local expression of HDPs. For instance, in mouse intestine, the expression of the mouse cathelicidin-related antimicrobial peptide (CRAMP), decreases, while cryptdin-related sequences (CRS) peptide and α -defensin expression increase with weaning [69]. These changes are important to maintain gut homeostasis as α -defensins have been shown to influence gut microbiota composition [70].

4.2 Antimicrobial strategies involving HDPs

Several HDP-based strategies can be applied that could potentially lead to a reduction of the use of antibiotics in animal husbandry. For example, feed additives can be used to enhance levels of endogenous HDP expression. Alternatively, HDP expression may be enhanced via breed selection or transgene approaches, which will not be discussed in this review. A third option would be to use HDPs as template for the development of novel antimicrobials and immunomodulators. Finally, HDPs may be used as adjuvants for augmenting particular types of immune responses upon vaccination.

4.2.1 Induction of endogenous HDP production

Several substances have been shown to upregulate endogenous HDP production and to counteract pathogen-mediated HDP suppression. Therefore, dietary supplementation of food/feed could be used to boost endogenous HDP expression levels and improve the outcome of diseases. Short-chain fatty acids propionate, butyrate, and isobutyrate and the flavanoid flavone are known to regulate colon cell differentiation and increase LL-37 expression in human colonocytes [71, 72]. Polyunsaturated fatty acids (PUFA) induce hBD-1 expression in these cells [73]. Similarly, butyrate analogs can induce defensin and cathelicidin transcription in porcine epithelial cells and macrophages [74]. *M. tuberculosis*-mediated LL-37 suppression in humans could be overcome by treatment with the butyrate analog phenylbutyrate and the vitamin D3 analog 1,25[OH]2D3 separately, while a synergistic action was observed for the combined treatment [75]. In addition, 1,25[OH]2D3 has also been reported to induce β -defensin expression in chicken peripheral blood mononuclear cells (PBMCs) and embryonic intestinal epithelial cells [76]. Oral butyrate treatment of experimental Shigellosis upregulated the production of LL-37 homolog CAP-18 (18-kDa cationic antimicrobial protein) in rabbits and reduced the clinical illness and bacterial load in stools [77]. Similar findings were obtained for phenylbutyrate against Shigellosis [78] and enteropathogenic *E. coli* associated diarrhea [79]. Sulforaphane, a phytochemical produced in cruciferous vegetables, increased hBD-2

transcription in colonocytes [80]. The mode of action of sulforaphane and butyrate analog-induced HDP production is based on inhibition of histone deacetylases (HDACs) leading to chromatin hyperacetylation and increased gene expression [71, 80]. Not surprisingly, the HDAC inhibitor Entinostat increased both LL-37 and hBD1 transcription in a human intestinal cell line. Entinostat-induced LL-37 expression was mediated via the STAT3-HIF1 α (signal transducer and activator of transcription 3-hypoxia-inducible factor 1- α) pathway in vitro and impaired in vivo in macrophages obtained from a STAT3 deficient patient [81]. A single dose of live-attenuated oral polio vaccine (OPV) and Bacillus Calmette-Guérin (BCG) vaccine within 48 h of birth increased gut LL-37 production in infants at 6 weeks of age, possibly by OPV stimulation of T cell production of IL-17 (interleukin-17) and IL-22, known regulators of mucosal LL-37 expression [82]. The adenylyl cyclase agonist forskolin induced avian β -defensin-9 (AVBD9) expression in chicken crop tissue [83] and LL-37 in undifferentiated human mucosal epithelial cells [84], whereas in butyrate-differentiated mucosal epithelial cells forskolin suppressed defensin and cathelicidin production [85] implicating a role for cyclic AMP in HDP regulation.

Probiotics can also be used to enhance endogenous expression of HDPs. Lactobacillus GG treatment of patients with oesophagitis was found to induce the transcription of several immune-related genes including human α -defensin 1 (HNP1) in duodenal mucosa [86]. Other lactobacillus strains and *E. coli* Nissle 1917 flagellin induced HBD-2 production in Caco-2 cells [87, 88]. In a 3 months-trial involving healthy children receiving *Lactobacillus paracasei*-fermented cow's milk compared to a placebo group, dietary intake of *L. paracasei*-fermented milk resulted in a net increase in fecal concentrations of LL-37, α -defensins (HNP1–3), and hBD2 that were negatively associated with the occurrence of common infectious diseases, respiratory tract infections and acute gastrointestinal infections [89]. L-Isoleucine induced β -defensin expression that was associated with less tissue damage and lower bacterial loads [90]. Arginine and albumin induced hBD-1 in human colonocytes [73]. Branched amino acids isoleucine, leucine and valine elevated the in vivo transcription of β -defensin-1, -2, -114, and -129 in porcine small intestine [91]. Thus, dietary administration is a possible route to elevate HDP production but care should be taken that a proper balance is maintained to ensure homeostasis.

4.2.2 HDP-derived antimicrobials

Due to their broad spectrum of antimicrobial activities HDPs are of interest as a novel class of antimicrobials. Unlike conventional antibiotics which readily induce

resistance, in many cases HDPs deploy multiple mechanisms to kill microbes including inhibition of cell division, protein synthesis and DNA replication [64, 92]. A few species, e.g. *Burkholderia* spp. are highly resistant to the direct antimicrobial action of HDPs. However, co-evolution of microbes and HDPs for millennia has not led to ubiquitous resistance against HDPs [93]. Still several pathogens have developed immune evasion strategies to protect against HDPs. The major virulence proteins of enteric pathogens *Vibrio cholera* (cholera toxin) and enterotoxigenic *E. coli* (labile toxin) down-regulate hBD1 and LL-37 production by intestinal epithelium [85]. Similarly, *Shigella*, a major cause of infant mortality and morbidity in developing countries, is able to down-regulate LL-37 and hBD1 in human rectal epithelium [77]. *Campylobacter jejuni* strains, that are highly susceptible to the chicken CATH-2 peptide that is abundantly present in chicken heterophils, appear to down-regulate CATH-2 expression as part of their immune evasion strategy [94]. Similarly, *Mycobacterium tuberculosis* infection of human macrophages suppresses LL-37 expression and autophagy-related genes at the mRNA and protein level [75].

Interaction between HDPs and the microbial membrane is thought to occur first through electrostatic interaction followed by insertion of hydrophobic groups into the lipid bilayer and transfer in or through the bilayer leading to transient pore formation and binding to RNA, DNA and proteins. Although not entirely impossible, development of systematic microbial resistance to HDPs is greatly hampered by the fact that microbes would need to reorganize their cell membrane composition to avoid peptide binding and membrane permeation. Thus, the same care and prudence involved in conventional antibiotic use should be taken when HDPs are therapeutically used for their direct antimicrobial activity. Several HDP-derived peptides have been tested in preclinical and clinical trials. Synthetic LL-37 has shown efficacy as a topical antibiotic for treatment of “hard-to-heal” venous leg ulcers in phase I/II clinical trials [95]. Analogs of bovine indolicidin (Omiganan/MSI78), frog magainin 2 (Pexiganan/MX-226/MBI-226), porcine protegrin 1 (Iseiganan/IB-367) were pursued in phase III clinical trials as a topical antiseptic and treatment of severe acne and rosacea, as topical antibiotic, and as antibiotic against oral mucositis in patients undergoing radiation therapy, and showed a similar efficacy but no advantage to existing therapies [93]. It may be concluded that the development of HDPs as alternative antimicrobials may be more successful for topical rather than systemic use.

4.2.3 HDP-derived immunomodulators

A most promising strategy is the use of HDPs as immunomodulators. Under physiological conditions, antimicrobial actions of HDPs may be impaired by the presence of salt, serum and charged molecules (glycosaminoglycans (GAGs), DNA) [96], but despite this, HDPs have been shown to modulate immunity and the function of immune cells [96, 97]. An important feature of HDPs is their capacity to modulate the differentiation of antigen presenting cells, such as dendritic cells and macrophages. Dendritic cells (DCs) are instrumental in coordinating an appropriate T cell response to infections. The environment in which DCs mature greatly influences their phenotype and plasticity. In the presence of LL-37 differentiation of human peripheral blood monocytes to immature DCs resulted in upregulation of antigen presentation markers HLA-DR (human leukocyte antigen-antigen D related) and CD86 (cluster of differentiation 86) [98], whereas LL-37-derived mature DCs exhibited a Th1 (type 1 helper T cells) cytokine profile and stimulated proliferation of IFN- γ (interferon- γ) producing T cells [99]. The chicken cathelicidin CATH-2 was shown to modulate immune responses of chicken mononuclear phagocytes and induced antigen presentation [100]. LL-37 modulation of DC differentiation was G-protein coupled receptor (GPCR) mediated and occurred early in differentiation [99]. The presence of LL-37 during or after differentiation of M2-polarized macrophages (by macrophage colony stimulating factor, M-CSF) skewed macrophage polarization towards a pro-inflammatory phenotype upon LPS stimulation, i.e. CD163^{low}, IL-10^{low}, IL12p40^{high} [101]. LL-37 did not affect polarization of fully differentiated M1-polarized macrophages (by granulocyte-macrophage colony stimulating factor, GM-CSF), but enhanced GM-CSF-driven macrophage differentiation [101].

Both the α -defensin HNP-1 and the β -defensin hBD-1 promote maturation of monocyte-derived DCs resulting in enhanced expression of maturation marker CD83, antigen presentation markers CD80, CD86, CD40, HLA-DR and scavenger receptor CD91 that also recognize defensins as ligands, suggesting the existence of an auto-crine activation loop by which defensins may amplify their own effects [102, 103]. Phagocytosis via integrin Mac-1 of Gram-negative and Gram-positive bacteria by macrophages could be promoted by coating bacteria with LL-37 [104]. HDPs may affect wound healing in several ways, by promoting neovascularization and angiogenesis, stimulating extracellular matrix proteoglycan production, promoting re-epithelization, and managing of the microbial burden through their antimicrobial properties [105–107].

A prime example of the prophylactic use of HDP-derived peptides is avian and fish immunomodulation in ovo. Via this route biological agents are directly injected into the amnion fluid, which is then imbibed by the embryo and distributed throughout the respiratory and gastrointestinal tracts. The in ovo route has several advantages: (a) the peptide concentrations that are used are far below MIC (minimum inhibitory concentration) values, which excludes antibacterial activities and thus the risk of resistance development; (b) a low peptide dose is needed, which is beneficial from a cost of goods perspective; (c) in ovo vaccination of chickens at 18 days of embryonic development (3 days before egg hatch) is commonly used in the poultry industry; (d) this strategy creates a window of opportunity for modulation of the immune system at an early stage. Cuperus et al. demonstrated that in ovo prophylactic treatment with 1 mg/kg body weight of the D-amino acid analog of chicken cathelicidin-2 (DCATH-2) partially protects chickens against a respiratory *E. coli* infection 7 days after hatch [108], resulting in reduced mortality (30%), and reduced morbidity (63%) and respiratory bacterial load (>90% reduction) among surviving birds. Injection of fluorescently labelled DCATH-2 peptide via the in ovo route confirmed that DCATH-2 peptide accumulated, via uptake of amnion fluid, in the lungs and gastrointestinal tract within 24 h post-injection (pi). Similarly, injection of 2.6 ng/kg DCATH-2 into the yolk of 0.2–1.5 h post-fertilized zebrafish embryos delayed infection of a lethal dose of *Salmonella enteritidis* [109]. DCATH-2 treatment of zebrafish embryos in the absence of infection resulted in a marked increase (30%) of phagocytic cells [109]. These findings show that immunomodulation by HDP-derived peptides may cross the species barrier, thus theoretically the same peptide could be used to boost resistance against infectious diseases in multiple species.

Prophylactic application could also be done post-natally. Innate defense regulators (IDRs) are a group of small immunomodulatory peptides with weak or no antibacterial activity that were developed using the bovine cathelicidin bactenecin 2a (RLARIVVIRVAR-NH₂) as template. In vivo efficacy has been demonstrated for several IDRs against an invasive *Staphylococcus aureus* and systemic *E. coli* infection. Intraperitoneal treatment of mice with 8 mg/kg IDR-1002 (200 μ g/mouse) or 4 mg/kg IDR-HH2 4 h before infection with *Staphylococcus aureus* reduced the bacterial load in peritoneal lavage 24 h pi and was found to be monocyte-dependent and associated with increased leukocyte recruitment and chemokine production [110, 111]. Similar efficacy was observed for IDR-1002 against *E. coli* in this model [110].

4.2.4 HDPs as adjuvants for vaccines

HDPs have also gained interest as an adjunct to vaccines for human and veterinary applications. The role of adjuvants in vaccines is crucial as they augment the host immune response against often weakly immunogenic pathogen-derived antigens and are able to selectively bias this response towards a Th1 or Th2 response. Proper adjuvants and adjuvant combinations effectively enhance and modulate the immune response via one or more mechanisms such as by recruitment of immune cells to the administered antigen and enhance antigen presentation by APCs (antigen presenting cells). The multifaceted immunomodulatory properties of some HDPs and HDP-related peptides may be used to “skew” the immune response in the desired direction. This was shown for indolicidin, a short (13 aa) bovine cathelicidin peptide. Immunization of mice by co-administration of OVA (ovalbumin) with indolicidin biased to a type 2 response with increased IgG1 production and number of IL-5 producing cells, whereas co-administration with CpG-DNA and indolicidin at a 1:67 molar ratio augmented both IgG1 and IgG2a production. Addition of polyphosphazene (PP) during immunization with OVA/CpG-DNA/indolicidin further increased IgG2a production by threefold compared to OVA/CpG-DNA/indolicidin alone, suggesting a more balanced immune response [112]. Similarly, indolicidin enhanced the immune response to hen egg lysozyme (HEL) in cattle; re-stimulation of PBMCs obtained 14 days after 2nd immunization showed a higher number of IFN- γ secreting cells after immunization with HEL/CpG/indolicidin compared to HEL/CpG, whereas CpG addition to HEL did not. Immunization with HEL/CpG/indolicidin/PP raised the antigen-specific humoral (total IgG titer in serum) and long-lasting cell-mediated immune responses (number of IFN-gamma secreting cells) [113]. Immunization of mice with pertussis toxin (PT), IDR-HH2 and CpG-DNA (PT/CpG/IDR-HH2) led to a balanced Th1/Th2 response, augmenting toxin-associated IgG1 and IgG2a titers as well as IgA titers, whereas toxin alone (PT) or combined with CpG-DNA (PT/CpG) failed to induce a strong immune response [114]. Immunization with toxin and IDR-HH2 (PT/IDR-HH2) resulted in a Th2 biased response. Oral administration of LL-37-conjugated enhanced green fluorescent protein (EGFP-LL-37) to mice resulted in an enhanced and Th17-skewed T cell dependent antigen-specific antibody response without induction of oral tolerance compared to mice receiving EGFP alone (EGFP), indicating that HDPs may be used as mucosal immune adjuvants [115]. These studies show that HDP-derived peptides can be used as an adjuvant to boost the immune response as well as to skew this response in the desired direction.

4.2.5 HDPs as adjuncts in antibiotic therapy

The adjunctive use of HDPs in antibiotic therapy has been examined against experimental tuberculosis, systemic *E. coli* infection and cerebral malaria. *M. tuberculosis* (TB) infected mice were subcutaneously treated 15 days p.i. during 4 weeks, with daily doses of 25 mg/kg of the anti-TB drugs isoniazid and rifampicin and/or a weekly dose of 5 μ g/mouse of human neutrophil defensin-1 (HNP-1). Treatment with anti-TB drugs alone reduced the bacterial load by approx. 1 log unit in lungs, liver and spleen, whereas combined therapy with anti-TB drugs and HNP-1 augmented reduction of bacterial loads by eight- to tenfold in lungs and liver and by threefold in spleen [116]. In another study, neutropenic mice were challenged i.p. (intraperitoneal injection) with a lethal dose of *E. coli* and treated with the β -lactam antibiotic cefepime (0.2 mg/kg) or with the HDP magainin 2 (2 mg/mouse) alone raised survival to 20% at 10 days pi compared to 10% in control animals. Combined treatment of challenged mice with cefepime and magainin 2 raised survival to 62.5% [117]. Therapeutic efficacy of HDP-derived peptide IDR-1018 as adjunctive treatment for cerebral malaria was tested in a preclinical model in which mice were infected with *Plasmodium berghei*-infected erythrocytes and on day 4 of infection were daily treated with anti-malarial drugs pyrimethamine and chloroquine up to 11 day pi [118]. Treatment with anti-malarials protected only 41% of the mice, whereas adjunctive therapy with a single i.v. (intravenous injection) dose of IDR-1018 at day 4, 5 and 6 increased survival to 68%. Interestingly, IDR-1018 treatment did not affect parasitemia and its adjunctive protection against late-stage malaria was linked to reduced inflammation. Currently, few immunomodulatory HDP analogs are being pursued in preclinical or clinical trials. In conclusion, HDPs can be used (1) prophylactically in ovo or postnatally, (2) as an adjuvant to vaccines, and (3) therapeutically as adjunct to conventional antibiotics or directly as antimicrobials.

5 Conclusions

For antibacterial products based on innate defense molecules to become attractive products as alternatives to antibiotics in animal husbandry it is necessary to match the low cost, efficiency and ease of use of traditional antibiotics. In addition, these products should be broadly applicable, have low adverse effect levels and must be safe, as well as being acceptable to consumers.

Development of host defense peptide-based immunomodulators is a challenge, but with potentially great rewards. The lack of translation of in vitro to in vivo immunomodulatory activities and challenges concerning choice of administration routes makes it difficult and laborious to optimize activities of lead peptides. The costs

of large-scale production of synthetic and expressed peptide immunomodulators have decreased and because low doses are needed for immunomodulation costs of goods are, even for veterinary use, no major hurdle. However, the greatest challenge faced is getting immunomodulators approved by regulatory agencies under the current legislation. Approved efficacy and safety tests were developed to evaluate molecules with direct antimicrobial activities; however, these tests are not suitable to evaluate immunomodulators.

In contrast, it will probably be possible to categorize products based on purified natural immunoglobulin pools for oral administration as feed supplements with much lower regulatory hurdles to overcome. Also, production costs can be kept at a level that makes their large-scale use in animal production economically feasible for the producers. However, challenges remain with immunoglobulin based products, including proving efficiency against relevant infections of production animals, obtaining reproducible, stable and consistently active products, optimally formulated for action in the gut and last but not least to ensure the absence of unwanted agents, especially viruses in products produced from blood.

In conclusion, innate host defense mechanisms offer interesting modes of actions for new strategies for counteracting microbial infections and disease in animal husbandry.

Host defense peptides offer several modes of use and—as they have a dual mode of action—may be used with a low risk of inducing AMR. Likewise, immunoglobulins are nature's own multi-target anti-pathogen effector molecules.

These innate host defense derived molecules provide general and rapid protective measures against infections, delaying establishment, growth and spread of the infection, allowing the adaptive immune system time to develop highly specific and high-affinity cellular and humoral defenses factors taking over protection in time to prevent or significantly slow down disease development. Most importantly, based on anti-bacterial mechanisms tested by the evolution they must be assumed to carry a very low risk of inducing new classes of resistance traits in bacteria and therefore constitute real alternatives to existing antibiotics.

Abbreviations

AMR: antimicrobial resistance; APCs: antigen presenting cells; AVBD9: avian β -defensin-9; BCG: *Bacillus Calmette–Guérin*; CAP-18: 18-kDa cationic antimicrobial protein; CATH-2: chicken cathelicidin 2; CCR: chemokine receptor; CD: cluster of differentiation; CRAMP: cathelicidin-related antimicrobial peptide; CRS-peptides: cryptdin-related sequences peptides; DCATH-2: D-amino acid analog of chicken cathelicidin-2; DCs: dendritic cells; EGFP: enhanced green fluorescent protein; FRP: N-formyl peptide receptor; GAGs: glycosaminoglycans; G-CSF: granulocyte colony stimulating factor; GM-CSF: granulocyte–macrophage colony stimulating factor; GPCR: G-protein coupled receptor;

hBD: human β -defensin; HDACs: histone deacetylases; HDPs: host defense peptides; HEL: hen egg lysozyme; HIF-1- α : hypoxia-inducible factor 1- α ; HLA-DR: human leukocyte antigen-antigen D related; HNP1: human α -defensin 1; IDRs: innate defense regulators; IFN- γ : interferon- γ ; Ig: immunoglobulin; IL: interleukin; LL-37: human cathelicidin; LPS: lipopolysaccharides; mBD: mouse β -defensin; M-CSF: macrophage colony stimulating factor; MDP: muramyl dipeptide; MIC: minimum inhibitory concentration; MMP-7: matrix metalloproteinase-7; NK cells: natural killer cells; NOD receptor: nucleotide-binding oligomerization domain-like receptor; NNPD: new neonatal porcine diarrhea; OPV: oral polio vaccine; OVA: ovalbumin; PAMPs: pathogen associated molecular patterns; PBMCs: peripheral blood mononuclear cells; PCV2: porcine circovirus type 2; PED: porcine endemic diarrhea virus; PEG: polyethylene glycol; PP: polyphosphazene; PRRSV: porcine respiratory and reproductive syndrome virus; PT: pertussis toxin; PUFA: polyunsaturated fatty acids; PWD: postweaning disease; pplgG: purified porcine IgG; slgA: secretory IgA; SDP: spray-dried plasma; STAT3: signal transducer and activator of transcription 3; TB: tuberculosis; Th1: type 1 helper T cells; NAG: *N*-acetyl-D-glucosamine; FUC: α -L-fucose; BMA: β -D-mannose; MAN: α -D-mannose; GAL: β -D-galactose; FUL: β -L-fucose.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Initial drafts of the manuscript were made by AvD and CJH; PMHH and HPH completed the review. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank the members of the Alternatives to Antibiotics Scientific Committee: Cyril G. Gay, USDA/ARS; Elisabeth Erlacher-Vindel, OIE; Margot Raicek, OIE; Hyun Lillehoj, USDA/ARS; Dennis M. Dixon, NIH/NIAID; Karin Hoelzer, Pew Charitable Trust; Chengbo Yang, University of Manitoba; Faye Ioannou, European Medicines Agency; Cindy L. Burnsteel, FDA; Filip van Immerseel, Ghent University; Kristian Møller, DTU; Bruce Seal, Oregon State University; Yanhong Liu, University of California; Jian Peng, Huazhong Agricultural University; Djamel Drider, Lille University; Thierry Pineau, INRA and Gary Sherman, USDA/NIFA. We also acknowledge the support provided by the ATA Symposium Organizing Committee and express our sincere thanks to Monique Éloit and staff at the OIE for hosting the symposium.

Funding

This work was partly supported by the Immuno Valley ALTANT ASIA2 Program Grant of the Dutch Ministry of Economic Affairs (HPH and AvD).

Author details

¹ Division Molecular Host Defence, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. ² Innate Immunology Group, National Veterinary Institute, Technical University of Denmark, Kongens Lyngby, Denmark.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 4 December 2017 Accepted: 28 June 2018

Published online: 31 July 2018

References

1. DANMAP2016 (2017) Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark
2. ESVAC (2013) Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011. Third ESVAC report
3. ESVAC (2015) Sales of veterinary antimicrobial agents in 26 EU/EEA countries in 2013. Fifth ESVAC report
4. Speksnijder DC, Mevius DJ, Bruschke CJM, Wagenaar JA (2015) Reduction of veterinary antimicrobial use in the Netherlands. The Dutch success model. *Zoonoses Public Health* 62(Suppl 1):79–87

5. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ (2016) Trained immunity: a program of innate immune memory in health and disease. *Science* 352:aaf1098
6. Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG (2015) Trained innate immunity as underlying mechanism for the long-term, non-specific effects of vaccines. *J Leukoc Biol* 98:347–356
7. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Iffrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG (2012) Bacille Calmette–Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc Natl Acad Sci U S A* 109:17537–17542
8. Arts RJ, Blok BA, van Crevel R, Joosten LA, Aaby P, Benn CS, Netea MG (2015) Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes. *J Leukoc Biol* 98:129–136
9. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajani-Refah A, Maresse F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijnemga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG (2014) Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. *Science* 345:1251086
10. Hamon MA, Quintin J (2016) Innate immune memory in mammals. *Semin Immunol* 28:351–358
11. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Cramer R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, Frei R, Garbani M, Globinska A, Hess L, Huitema C, Kubo T, Komlosi Z, Konieczna P, Kovacs N, Kucuksezer UC, Meyer N, Morita H, Olzhausen J, O'Mahony L, Pezer M, Prati M, Rebane A, Rhyner C, Rinaldi A, Sokolowska M, Stanic B, et al. (2016) Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: receptors, functions, and roles in diseases. *J Allergy Clin Immunol* 138:984–1010
12. Ohno M, Natsume A, Wakabayashi T (2012) Cytokine therapy. *Adv Exp Med Biol* 746:86–94
13. Pham TA, Clare S, Goulding D, Arasteh JM, Stares MD, Browne HP, Keane JA, Page AJ, Kumasaka N, Kane L, Mottram L, Harcourt K, Hale C, Arends MJ, Gaffney DJ, Sanger Mouse Genetics P, Dougan G, Lawley TD (2014) Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. *Cell Host Microbe* 16:504–516
14. Goto Y, Obata T, Kunisawa J, Sato S, Ivanov II, Lamichhane A, Takeyama N, Kamioka M, Sakamoto M, Matsuki T, Setoyama H, Imaoka A, Uematsu S, Akira S, Domino SE, Kulig P, Becher B, Renauld JC, Sasakawa C, Umesaki Y, Benno Y, Kiyono H (2014) Innate lymphoid cells regulate intestinal epithelial cell glycosylation. *Science* 345:1254009
15. Rahman MM, Eo SK (2012) Prospects and challenges of using chicken cytokines in disease prevention. *Vaccine* 30:7165–7173
16. Hassfurther RL, TerHune TN, Canning PC (2015) Efficacy of polyethylene glycol-conjugated bovine granulocyte colony-stimulating factor for reducing the incidence of naturally occurring clinical mastitis in peri parturient dairy cows and heifers. *Am J Vet Res* 76:231–238
17. Hurley WL, Theil PK (2011) Perspectives on immunoglobulins in colostrum and milk. *Nutrients* 3:442–474
18. Hedegaard CJ, Heegaard PM (2016) Passive immunisation, an old idea revisited: basic principles and application to modern animal production systems. *Vet Immunol Immunopathol* 174:50–63
19. Weaver DM, Tyler JW, VanMetre DC, Hostetler DE, Barrington GM (2000) Passive transfer of colostral immunoglobulins in calves. *J Vet Intern Med* 14:569–577
20. Godden S (2008) Colostrum management for dairy calves. *Vet Clin North Am Food Anim Pract* 24:19–39
21. Moor K, Diard M, Sellin ME, Felmy B, Wotzka SY, Toska A, Bakkeren E, Arnoldini M, Bansept F, Co AD, Voller T, Minola A, Fernandez-Rodriguez B, Agatic G, Barbieri S, Piccoli L, Casiraghi C, Corti D, Lanzavecchia A, Regoes RR, Loverdo C, Stocker R, Brumley DR, Hardt WD, Slack E (2017) High-avidity IgA protects the intestine by enchainning growing bacteria. *Nature* 544:498–502
22. Nimmerjahn F, Gordan S, Lux A (2015) FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. *Trends Immunol* 36:325–336
23. Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. *Front Immunol* 5:520
24. Newby TJ, Bourne FJ (1976) Relative resistance of bovine and porcine immunoglobulins to proteolysis. *Immunol Commun* 5:631–635
25. Graham BS, Ambrosino DM (2015) History of passive antibody administration for prevention and treatment of infectious diseases. *Curr Opin HIV AIDS* 10:129–134
26. Calmette A (1896) The treatment of animals poisoned with snake venom by the injection of antivenomous serum. *Br Med J* 2:399–400
27. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. *Clin Microbiol Rev* 13:602–614
28. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. *Nature* 514:47–53
29. Marano G, Vaglio S, Pupella S, Faccio G, Catalano L, Liumbruno GM, Grazzini G (2016) Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus* 14:152–157
30. Fisher R, Borio L (2016) Ebola virus disease: therapeutic and potential preventative opportunities. In: Scheld W, Hughes J, Whitley R (eds) *Emerging infections*, Chapter 3. ASM Press, Washington
31. Ferreira AS, Barbosa FF, Tokach MD, Santos M (2009) Spray dried plasma for pigs weaned at different ages. *Recent Pat Food Nutr Agric* 1:231–235
32. Torralardona D (2010) Spray dried animal plasma as an alternative to antibiotics in weanling pigs. *Asian-Aust J Anim Sci* 23:131–148
33. Pierce JL, Cromwell GL, Lindemann MD, Russell LE, Weaver EM (2005) Effects of spray-dried animal plasma and immunoglobulins on performance of early weaned pigs. *J Anim Sci* 83:2876–2885
34. Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E, De Greve H, Depicker A (2013) Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic *Escherichia coli* infection. *Proc Natl Acad Sci U S A* 110:11809–11814
35. Bah CSF, Bekhit AEDA, Carne A, McConnell MA (2013) Slaughterhouse blood: an emerging source of bioactive compounds. *Compr Rev Food Sci Food Saf* 12:314–331
36. Kovacs-Nolan J, Mine Y (2012) Egg yolk antibodies for passive immunity. *Annu Rev Food Sci Technol* 3:163–182
37. Carlander D, Kollberg H, Wejaker PE, Larsson A (2000) Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. *Immunol Res* 21:1–6
38. Lihme A, Hansen MB, Andersen IV, Burnouff T (2010) A novel core fractionation process of human plasma by expanded bed adsorption chromatography. *Anal Biochem* 399:102–109
39. Hedegaard CJ, Strube ML, Hansen MB, Lindved BK, Lihme A, Boye M, Heegaard PM (2016) Natural pig plasma immunoglobulins have antibacterial effects: potential for use as feed supplement for treatment of intestinal infections in pigs. *PLoS One* 11:e0147373
40. Hedegaard CJ, Lauridsen C, Heegaard PMH (2017) Purified natural pig immunoglobulins can substitute dietary zinc in reducing piglet post weaning diarrhoea. *Vet Immunol Immunopathol* 186:9–14
41. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol* 24:1551–1557
42. van Dijk A, Tersteeg-Zijdeveld MH, Tjeerdma-van Bokhoven JL, Jansman AJ, Veldhuizen EJ, Haagsman HP (2009) Chicken heterophils are recruited to the site of *Salmonella* infection and release antibacterial mature Cathelicidin-2 upon stimulation with LPS. *Mol Immunol* 46:1517–1526
43. Petrov V, Funderburg N, Weinberg A, Sieg S (2013) Human beta defensin-3 induces chemokines from monocytes and macrophages: diminished activity in cells from HIV-infected persons. *Immunology* 140:413–420
44. Mookherjee N, Hamill P, Gardy J, Blimkie D, Falsafi R, Chikatamarla A, Arenillas DJ, Doria S, Kollmann TR, Hancock RE (2009) Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. *Mol Biosyst* 5:483–496

45. Bowdish DM, Davidson DJ, Speert DP, Hancock RE (2004) The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. *J Immunol* 172:3758–3765
46. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* 286:525–528
47. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPR1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. *J Exp Med* 192:1069–1074
48. Rohrl J, Yang D, Oppenheim JJ, Hehlhans T (2010) Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *J Immunol* 184:6688–6694
49. Schaal JB, Tran D, Tran P, Osapay G, Trinh K, Roberts KD, Brasky KM, Tongaonkar P, Ouellette AJ, Selsted ME (2012) Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis. *PLoS One* 7:e51337
50. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. *J Immunol* 176:2455–2464
51. Coorens M, Scheenstra MR, Veldhuizen EJ, Haagsman HP (2017) Inter-species cathelicidin comparison reveals divergence in antimicrobial activity, TLR modulation, chemokine induction and regulation of phagocytosis. *Sci Rep* 7:40874
52. Liu H, Yu H, Gu Y, Xin A, Zhang Y, Diao H, Lin D (2013) Human beta-defensin DEF126 is capable of inhibiting LPS-mediated inflammation. *Appl Microbiol Biotechnol* 97:3395–3408
53. Coorens M, van Dijk A, Bikker F, Veldhuizen EJ, Haagsman HP (2015) Importance of endosomal cathelicidin degradation to enhance DNA-Induced chicken macrophage activation. *J Immunol* 195:3970–3977
54. Tewary P, de la Rosa G, Sharma N, Rodriguez LG, Tarasov SG, Howard OM, Shiota H, Steinhagen F, Klinman DM, Yang D, Oppenheim JJ (2013) β -Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN- α production by human plasmacytoid dendritic cells, and promote inflammation. *J Immunol* 191:865–874
55. Hancock RE, Haney EF, Gill EE (2016) The immunology of host defence peptides: beyond antimicrobial activity. *Nat Rev Immunol* 16:321–334
56. Kannan L, Rath NC, Liyanage R, Lay JO Jr (2009) Direct screening identifies mature beta-defensin 2 in avian heterophils. *Poult Sci* 88:372–379
57. Cuperus T, van Dijk A, Dwars RM, Haagsman HP (2016) Localization and developmental expression of two chicken host defense peptides: cathelicidin-2 and avian beta-defensin 9. *Dev Comp Immunol* 61:48–59
58. van Es JH, Jay P, Gregorieff A, van Gijn ME, Jonkheer S, Hatzis P, Thiele A, van den Born M, Begthel H, Brabletz T, Taketo MM, Clevers H (2005) Wnt signalling induces maturation of Paneth cells in intestinal crypts. *Nat Cell Biol* 7:381–386
59. Putsep K, Axelsson LG, Boman A, Midtvedt T, Normark S, Boman HG, Andersson M (2000) Germ-free and colonized mice generate the same products from enteric prodefensins. *J Biol Chem* 275:40478–40482
60. O'Neil DA (2003) Regulation of expression of beta-defensins: endogenous enteric peptide antibiotics. *Mol Immunol* 40:445–450
61. Nagaoka I, Hirata M, Sugimoto K, Tsutsumi-Ishii Y, Someya A, Saionji K, Igari J (1998) Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow. *J Leukoc Biol* 64:845–852
62. Yount NY, Yuan J, Tarver A, Castro T, Diamond G, Tran PA, Levy JN, McCullough C, Cullor JS, Bevins CL, Selsted ME (1999) Cloning and expression of bovine neutrophil beta-defensins. Biosynthetic profile during neutrophilic maturation and localization of mature peptide to novel cytoplasmic dense granules. *J Biol Chem* 274:26249–26258
63. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood* 97:3951–3959
64. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME (1989) Interaction of human defensins with *Escherichia coli*. Mechanism of bactericidal activity. *J Clin Invest* 84:553–561
65. Gallo RL, Hooper LV (2012) Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol* 12:503–516
66. O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, Kagnoff MF (1999) Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. *J Immunol* 163:6718–6724
67. Gerstel U, Czapp M, Bartels J, Schroder JM (2009) Rhamnolipid-induced shedding of flagellin from *Pseudomonas aeruginosa* provokes hBD-2 and IL-8 response in human keratinocytes. *Cell Microbiol* 11:842–853
68. Dorschner RA, Lin KH, Murakami M, Gallo RL (2003) Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. *Pediatr Res* 53:566–572
69. Tourneur E, Chassin C (2013) Neonatal immune adaptation of the gut and its role during infections. *Clin Dev Immunol* 2013:270301
70. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Tegatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA (2010) Enteric defensins are essential regulators of intestinal microbial ecology. *Nat Immunol* 11:76–83
71. Schaubert J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, Melcher R, Agerberth B, Luhrs H, Gudmundsson GH (2013) Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. *Gut* 52:735–741
72. Jiang W, Sunkara LT, Zeng X, Deng Z, Myers SM, Zhang G (2013) Differential regulation of human cathelicidin LL-37 by free fatty acids and their analogs. *Peptides* 50:129–138
73. Sherman H, Chapnik N, Froy O (2006) Albumin and amino acids upregulate the expression of human beta-defensin 1. *Mol Immunol* 43:1617–1623
74. Zeng X, Sunkara LT, Jiang W, Bible M, Carter S, Ma X, Qiao S, Zhang G (2013) Induction of porcine host defense peptide gene expression by short-chain fatty acids and their analogs. *PLoS One* 8:e72922
75. Rekha RS, Rao Muvva SS, Wan M, Raqib R, Bergman P, Brighenti S, Gudmundsson GH, Agerberth B (2015) Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of *Mycobacterium tuberculosis* in human macrophages. *Autophagy* 11:1688–1699
76. Zhang L, Lu L, Li S, Zhang G, Ouyang L, Robinson K, Tang Y, Zhu Q, Li D, Hu Y, Liu Y (2016) 1,25-dihydroxyvitamin-D3 induces avian beta-defensin gene expression in chickens. *PLoS One* 11:e0154546
77. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Nasirul Islam KM, Gudmundsson GH, Andersson J, Agerberth B (2006) Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. *Proc Natl Acad Sci U S A* 103:9178–9183
78. Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, Bergman P, Gudmundsson GH, Agerberth B, Raqib R (2011) Phenylbutyrate counteracts *Shigella* mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. *PLoS One* 6:e20637
79. Al-Mamun A, Mily A, Sarker P, Tiash S, Navarro A, Akter M, Talukder KA, Islam MF, Agerberth B, Gudmundsson GH, Cravioto A, Raqib R (2013) Treatment with phenylbutyrate in a pre-clinical trial reduces diarrhea due to enteropathogenic *Escherichia coli*: link to cathelicidin induction. *Microbes Infect* 15:939–950
80. Schwab M, Reyniers V, Loitsch S, Steinhilber D, Schroder O, Stein J (2008) The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells. *Immunology* 125:241–251
81. Miraglia E, Nylen F, Johansson K, Arner E, Cebula M, Farmand S, Ottosson H, Stromberg R, Gudmundsson GH, Agerberth B, Bergman P (2016) Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1 α transcription factors. *Sci Rep* 6:33274
82. Alam MJ, Rashid MM, Kabir Y, Raqib R, Ahmad SM (2015) On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: a natural experiment. *Vaccine* 33:18–21
83. Sunkara LT, Zeng X, Curtis AR, Zhang G (2014) Cyclic AMP synergizes with butyrate in promoting beta-defensin 9 expression in chickens. *Mol Immunol* 57:171–180

84. Chakraborty K, Maity PC, Sil AK, Takeda Y, Das S (2009) cAMP stringently regulates human cathelicidin antimicrobial peptide expression in the mucosal epithelial cells by activating cAMP-response element-binding protein, AP-1, and inducible cAMP early repressor. *J Biol Chem* 284:21810–21827
85. Chakraborty K, Ghosh S, Koley H, Mukhopadhyay AK, Ramamurthy T, Saha DR, Mukhopadhyay D, Roychowdhury S, Hamabata T, Takeda Y, Das S (2008) Bacterial exotoxins downregulate cathelicidin (hCAP-18/LL-37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. *Cell Microbiol* 10:2520–2537
86. Di Caro S, Tao H, Grillo A, Elia C, Gasbarrini G, Sepulveda AR, Gasbarrini A (2005) Effects of *Lactobacillus* GG on genes expression pattern in small bowel mucosa. *Dig Liver Dis* 37:320–329
87. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K (2007) Induction of human beta-defensin 2 by the probiotic *Escherichia coli* Nissle 1917 is mediated through flagellin. *Infect Immun* 75:2399–2407
88. Schlee M, Harder J, Kolen B, Stange EF, Wehkamp J, Fellermann K (2008) Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. *Clin Exp Immunol* 151:528–535
89. Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nuges R, Ferri P, Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R (2017) Cow's milk and rice fermented with *Lactobacillus paracasei* CBA L74 prevent infectious diseases in children: a randomized controlled trial. *Clin Nutr* 36:118–125
90. Fehlbaum P, Rao M, Zasloff M, Anderson GM (2000) An essential amino acid induces epithelial beta-defensin expression. *Proc Natl Acad Sci U S A* 97:12723–12728
91. Ren M, Zhang S, Liu X, Li S, Mao X, Zeng X, Qiao S (2016) Different lipopolysaccharide branched-chain amino acids modulate porcine intestinal endogenous beta-defensin expression through the Sirt1/ERK/90RSK pathway. *J Agric Food Chem* 64:3371–3379
92. Subbalakshmi C, Sitaram N (1998) Mechanism of antimicrobial action of indolicidin. *FEMS Microbiol Lett* 160:91–96
93. Fjell CD, Hiss JA, Hancock RE, Schneider G (2011) Designing antimicrobial peptides: form follows function. *Nat Rev Drug Discov* 11:37–51
94. van Dijk A, Herrebout M, Tersteeg-Zijderdeld MH, Tjeerdma-van Bokhoven JL, Bleumink-Pluym N, Jansman AJ, Veldhuizen EJ, Haagsman HP (2012) *Campylobacter jejuni* is highly susceptible to killing by chicken host defense peptide cathelicidin-2 and suppresses intestinal cathelicidin-2 expression in young broilers. *Vet Microbiol* 160:347–354
95. Gronberg A, Mahlapuu M, Stahle M, Whately-Smith C, Rollman O (2014) Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. *Wound Repair Regen* 22:613–621
96. Hilchie AL, Wuert K, Hancock RE (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. *Nat Chem Biol* 9:761–768
97. Hancock RE, Nijnik A, Philpott DJ (2012) Modulating immunity as a therapy for bacterial infections. *Nat Rev Microbiol* 10:243–254
98. Bandholtz L, Ekman GJ, Vilhelmsson M, Buentke E, Agerberth B, Scheynius A, Gudmundsson GH (2006) Antimicrobial peptide LL-37 internalized by immature human dendritic cells alters their phenotype. *Scand J Immunol* 63:410–419
99. Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, Hancock RE, Speert DP (2004) The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. *J Immunol* 172:1146–1156
100. Kraaij MD, van Dijk A, Haagsman HP (2017) CATH-2 and LL-37 increase mannose receptor expression, antigen presentation and the endocytic capacity of chicken mononuclear phagocytes. *Mol Immunol* 90:118–125
101. van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ottenhoff TH, van Dissel JT, Drijfhout JW, Hiemstra PS, Nibbering PH (2010) LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. *J Immunol* 185:1442–1449
102. Presicce P, Giannelli S, Taddeo A, Villa ML, Della Bella S (2009) Human defensins activate monocyte-derived dendritic cells, promote the production of proinflammatory cytokines, and up-regulate the surface expression of CD91. *J Leukoc Biol* 86:941–948
103. Cappelletti M, Presicce P, Calcaterra F, Mavilio D, Della Bella S (2015) Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins. *Immunology* 144:661–667
104. Lishko VK, Moreno B, Podolnikova NP, Ugarova TP (2016) Identification of human cathelicidin peptide LL-37 as a ligand for macrophage integrin alphaMbeta2 (Mac-1, CD11b/CD18) that promotes phagocytosis by opsonizing bacteria. *Res Rep Biochem* 2016:39–55
105. Steintraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, Langer S, Kesting M, Steinau H, Eriksson E, Hirsch T (2008) Host defense peptides in wound healing. *Mol Med* 14:528–537
106. Ramos R, Silva JP, Rodrigues AC, Costa R, Guardao L, Schmitt F, Soares R, Vilanova M, Domingues L, Gama M (2011) Wound healing activity of the human antimicrobial peptide LL37. *Peptides* 32:1469–1476
107. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M (2003) The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. *J Invest Dermatol* 120:379–389
108. Cuperus T, van Dijk A, Matthijs MG, Veldhuizen EJ, Haagsman HP (2016) Protective effect of *in ovo* treatment with the chicken cathelicidin analog D-CATH-2 against avian pathogenic *E. coli*. *Sci Rep* 6:26622
109. Schneider VA, van Dijk A, van der Sar AM, Kraaij MD, Veldhuizen EJ, Haagsman HP (2016) Prophylactic administration of chicken cathelicidin-2 boosts zebrafish embryonic innate immunity. *Dev Comp Immunol* 60:108–114
110. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, Easton DM, Mayer ML, Mullaly SC, Kindrachuk J, Jenssen H, Hancock RE (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. *J Immunol* 184:2539–2550
111. Rivas-Santiago B, Castaneda-Delgado JE, Rivas Santiago CE, Waldbrook M, Gonzalez-Curiel I, Leon-Contreras JC, Enciso-Moreno JA, del Villar V, Mendez-Ramos J, Hancock RE, Hernandez-Pando R (2013) Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against *Mycobacterium tuberculosis* infections in animal models. *PLoS One* 8:e59119
112. Kovacs-Nolan J, Latimer L, Landi A, Jenssen H, Hancock RE, Babiuk LA, van Drunen Littel S, van den Hurk S (2009) The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. *Vaccine* 27:2055–2064
113. Kovacs-Nolan J, Mapletto JW, Latimer L, Babiuk LA, Hurk S (2009) CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. *Vaccine* 27:2048–2054
114. Kindrachuk J, Jenssen H, Elliott M, Townsend R, Nijnik A, Lee SF, Gerds V, Babiuk LA, Halperin SA, Hancock RE (2009) A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. *Vaccine* 27:4662–4671
115. Kim SH, Yang IY, Kim J, Lee KY, Jang YS (2015) Antimicrobial peptide LL-37 promotes antigen-specific immune responses in mice by enhancing Th17-skewed mucosal and systemic immunities. *Eur J Immunol* 45:1402–1413
116. Kalita A, Verma I, Khuller GK (2004) Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. *J Infect Dis* 190:1476–1480
117. Darveau RP, Cunningham MD, Seachord CL, Cassiano-Clough L, Cosand WL, Blake J, Watkins CS (1991) beta-Lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo. *Antimicrob Agents Chemother* 35:1153–1159
118. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, Mayer ML, Ma S, Kindrachuk J, Finlay BB, Brinkman FS, Smyth GK, Hancock RE, Schofield L (2012) Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. *Sci Transl Med* 4:135ra164